Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Interim data from Schering-Plough's narlaprevir Phase IIa study

Interim data from Schering-Plough's narlaprevir Phase IIa study

Mortal combination of health problems that can double the risk of heart attack identified

Mortal combination of health problems that can double the risk of heart attack identified

Combination of inhibitor and antioxidants may help prevent diabetes complications

Combination of inhibitor and antioxidants may help prevent diabetes complications

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Luminous Medical to incorporate glucose sensor in its automated blood glucose monitor

Luminous Medical to incorporate glucose sensor in its automated blood glucose monitor

Low levels of ROS might protect us from diabetes, says study

Low levels of ROS might protect us from diabetes, says study

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.